{"id":"clopidogrel-sr25990c","safety":{"commonSideEffects":[{"rate":"1–3","effect":"Bleeding (major and minor)"},{"rate":"5–10","effect":"Dyspepsia"},{"rate":"2–4","effect":"Rash"},{"rate":"2–3","effect":"Diarrhea"},{"rate":"<0.1","effect":"Thrombotic thrombocytopenic purpura (TTP)"}]},"_chembl":{"chemblId":"CHEMBL1771","moleculeType":"Small molecule","molecularWeight":"321.83"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Clopidogrel is a prodrug that requires hepatic metabolism to form its active metabolite, which then binds irreversibly to the P2Y12 receptor on platelet surfaces. This prevents ADP-mediated platelet activation and aggregation, reducing thrombotic events. The antiplatelet effect is cumulative and reaches steady state after 3–7 days of daily dosing.","oneSentence":"Clopidogrel is a thienopyridine antiplatelet agent that irreversibly inhibits ADP-induced platelet aggregation by blocking the P2Y12 adenosine diphosphate receptor on platelets.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:43:32.568Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome (unstable angina and non-ST-elevation myocardial infarction)"},{"name":"ST-elevation myocardial infarction"},{"name":"Peripheral arterial disease"},{"name":"Ischemic stroke or transient ischemic attack"},{"name":"Secondary prevention of atherothrombotic events"}]},"trialDetails":[{"nctId":"NCT00249873","phase":"PHASE3","title":"Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-06","conditions":"Atrial Fibrillation, Vascular Risk","enrollment":7554},{"nctId":"NCT00386191","phase":"PHASE4","title":"Safety and Efficacy of Clopidogrel for Cerebral Infarction Treatment","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-09","conditions":"Cerebral Infarction","enrollment":1110},{"nctId":"NCT00243178","phase":"PHASE3","title":"Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W)","status":"TERMINATED","sponsor":"Sanofi","startDate":"2003-07","conditions":"Atrial Fibrillation, Vascular Risk","enrollment":6706},{"nctId":"NCT00325390","phase":"PHASE3","title":"Efficacy and Safety in Patients With Acute Coronary Syndrome Without ST-Segment Elevation","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-07","conditions":"Platelet Aggregation Inhibitors, NSTEACS","enrollment":800}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Plavix®"],"phase":"marketed","status":"active","brandName":"clopidogrel (SR25990C)","genericName":"clopidogrel (SR25990C)","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Clopidogrel is a thienopyridine antiplatelet agent that irreversibly inhibits ADP-induced platelet aggregation by blocking the P2Y12 adenosine diphosphate receptor on platelets. Used for Acute coronary syndrome (unstable angina and non-ST-elevation myocardial infarction), ST-elevation myocardial infarction, Peripheral arterial disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}